Sichuan Creed, the only short-acting muscle relaxant in China, won the first imitation!

According to the latest data from Meinnet.
com, the sales scale of terminal muscle relaxants in China's public medical institutions in 2021H1 increased by 32.
47% year-on-year, and the total market share of TOP10 products exceeded 95%.
Ammonium has met the requirements for centralized procurement, and the muscle relaxant market will be reshuffled; although Micuronium has not been squeezed into the TOP10, its sales growth rate in 2021H1 leads all muscle relaxants, reaching 185.
71%, and is ranked in muscle relaxant products With the improvement year by year, Sichuan Creed successfully won the first imitation in April 2021
.
Muscle relaxant "Yi Ge" is included in centralized procurement, and the market is shuffled over 4 billion.
Muscle relaxants (hereinafter referred to as muscle relaxants) can selectively act on neuromuscular junctions, temporarily interfering with normal neuromuscular excitement transmission, and relaxing muscles
.
Muscle relaxants are mainly used for tracheal intubation during induction of surgical anesthesia or to maintain muscle relaxation during general anesthesia.
It can also be used to eliminate the antagonism of spontaneous breathing to the ventilator during mechanical ventilation in critically ill patients, and to treat tetanus, status epilepticus and other muscles Spastic disease
.
Muscle relaxants are mainly used in general anesthesia.
The commonly used muscle relaxants in anesthesiology are mainly divided into two categories, one is depolarizing muscle relaxants/non-competitive muscle relaxants, and the other is atracurium /Cisatracurium (medium-acting), rocuronium (medium-acting), micuronium (short-acting) and other non-depolarizing muscle relaxants/competitive muscle relaxants
.
In clinical practice, medium and short-acting non-depolarizing muscle relaxants are used more frequently
.
With the continuous increase in the number of hospitalizations and operating units in China's medical institutions, the muscle relaxant market is expanding year by year
.
According to data from Meinenet, in 2020, the sales volume of terminal muscle relaxants in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 4 billion yuan
.
With the normalization of the epidemic, the number of doctors and operating units in hospitals has gradually recovered, and the muscle relaxant market has recovered.
The sales scale of 2021H1 exceeded 2 billion yuan, an increase of 32.
47% over the same period last year.

.
Figure 1: Sales of terminal muscle relaxants in China's public medical institutions (unit: 10,000 yuan) Source: Mi Nei.
com.
China's public medical institutions' terminal competition pattern.
The market concentration of muscle relaxants in China's public medical institutions is relatively high.
Top 10 in the first half of 2021 The total market share of products exceeds 95%.
Although Micuronium has not been squeezed into the TOP10, its growth rate in 2021H1 is the highest among all muscle relaxants, reaching 185.
71%, and its ranking in muscle relaxants has increased year by year, from 2018 The 16th place in the year was raised to the 13th place in 2021H1, with a great market potential
.
Subdivided into anesthesiology muscle relaxants, non-depolarizing muscle relaxants are the most clinically used category.
Cisatracurium benzenesulfonate has a market share of over 70%, and rocuronium has a market share of 23%.
Immediately afterwards
.
Table 1: Sales of commonly used muscle relaxants in the terminal anesthesia department of Chinese public medical institutions in 2021H1 Source: Meinenet.
com.
The terminal competition pattern of Chinese public medical institutions.
Current cisatracurium besilate injections (including cisatracurium besilate and benzene for injection) Sulfonatracurium injection) has been included in the fifth batch of national centralized procurement, and the number of over-rated companies for rocuronium injection has reached 4, and it is highly probable that it will be selected in the seventh batch of centralized procurement
.
With the normalization of centralized procurement, the muscle relaxant market will continue to reshuffle, and the sales of stock products will be affected to a certain extent due to the sharp decline in prices.
Newly approved products are expected to quickly seize the market through winning bids
.
Table 2: Muscle relaxants that have been included in the national centralized procurement.
Source: Shanghai Sunshine Pharmaceutical Purchasing Network is the only short-acting muscle relaxant.
Sichuan Creed won the first imitation of Meinenet.
Data shows that currently 6 muscle relaxants have been approved or approved by companies.
It is deemed to have passed the consistency evaluation.
Among them, Sichuan Creed Pharmaceutical’s Micuronium Injection, Livzon Group Livzon Pharmaceutical Factory’s Dantrolene Sodium for Injection, and Wuhan Hengxinyuan Pharmaceutical’s Dantrolene Sodium Capsules are the first imitations ( The first imitation containing dosage form) was approved and deemed to have been reviewed
.
Table 3: Part of the over-evaluation status of muscle relaxants (including new classifications for production) Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Micuronium is highly selective and the only one that does not require anticholinesterase drug antagonism The non-depolarizing neuromuscular blocker is also the only short-acting muscle relaxant in China.
It has the advantages of rapid onset, reliable action, rapid recovery, no adverse cardiovascular reactions, no accumulation, etc.
, especially suitable for children and the elderly People and other special groups of people use
.
Micuronium satisfies the characteristics of an ideal muscle relaxant, and is more in line with the current rapid clinical development of accelerated rehabilitation surgery (ERAS) concept
.
Sichuan Creed Pharmaceutical's Micuronium Chloride Injection was approved for production in April 2021, and it is the first domestic imitation.
Many quality inspection indicators are in line with national regulations, and there is no difference compared with the original product
.
In addition, its registration standards have been upgraded twice compared with the original products, with stronger impurity detection capabilities, lower impurity content, and better quality control
.
In terms of muscle relaxants, Sichuan Creed Pharmaceuticals has created anesthesia line products with different effects and durations.
In addition to the above-mentioned micuronium injection, the company also has a long-acting muscle relaxant-pipecuronium for injection.
At present, only Hungarian Jirui and Sichuan Creed Pharmaceuticals have the approval for the production of this product in China
.
Note: The original text has been deleted.
Source: Minet.
com database